551 related articles for article (PubMed ID: 25301180)
1. Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V; Barnett AH
Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
White JR
Ann Pharmacother; 2015 May; 49(5):582-98. PubMed ID: 25712444
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.
Dailey G
J Diabetes; 2015 Jul; 7(4):448-61. PubMed ID: 25676662
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
9. [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Prázný M; Slíva J
Vnitr Lek; 2015 Feb; 61(2):175-8. PubMed ID: 25813264
[TBL] [Abstract][Full Text] [Related]
10. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Hu J; Zou P; Zhang S; Zhou M; Tan X
Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
[TBL] [Abstract][Full Text] [Related]
12. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Blevins T
Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
[TBL] [Abstract][Full Text] [Related]
15. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):211-223. PubMed ID: 27817207
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dixit D; Yoon Y; Volino LR; Mansukhani RP
Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949
[TBL] [Abstract][Full Text] [Related]
18. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Nauck MA
Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
20. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
